JP2012533066A5 - - Google Patents

Download PDF

Info

Publication number
JP2012533066A5
JP2012533066A5 JP2012519652A JP2012519652A JP2012533066A5 JP 2012533066 A5 JP2012533066 A5 JP 2012533066A5 JP 2012519652 A JP2012519652 A JP 2012519652A JP 2012519652 A JP2012519652 A JP 2012519652A JP 2012533066 A5 JP2012533066 A5 JP 2012533066A5
Authority
JP
Japan
Prior art keywords
apociii
level
diabetes
subject
subjects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012519652A
Other languages
English (en)
Japanese (ja)
Other versions
JP5876826B2 (ja
JP2012533066A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/040998 external-priority patent/WO2011005718A1/en
Publication of JP2012533066A publication Critical patent/JP2012533066A/ja
Publication of JP2012533066A5 publication Critical patent/JP2012533066A5/ja
Application granted granted Critical
Publication of JP5876826B2 publication Critical patent/JP5876826B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012519652A 2009-07-07 2010-07-03 糖尿病前症及び2型糖尿病におけるアポリポタンパク質ciii Active JP5876826B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22350209P 2009-07-07 2009-07-07
US61/223,502 2009-07-07
PCT/US2010/040998 WO2011005718A1 (en) 2009-07-07 2010-07-03 Apolipoprotein ciii in pre- and type 2 diabetes

Publications (3)

Publication Number Publication Date
JP2012533066A JP2012533066A (ja) 2012-12-20
JP2012533066A5 true JP2012533066A5 (enExample) 2013-05-30
JP5876826B2 JP5876826B2 (ja) 2016-03-02

Family

ID=43427312

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012519652A Active JP5876826B2 (ja) 2009-07-07 2010-07-03 糖尿病前症及び2型糖尿病におけるアポリポタンパク質ciii

Country Status (5)

Country Link
US (2) US20110008901A1 (enExample)
EP (1) EP2451466B1 (enExample)
JP (1) JP5876826B2 (enExample)
CN (1) CN102481319A (enExample)
WO (1) WO2011005718A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8557513B2 (en) * 2011-06-27 2013-10-15 Biocrine Ab Methods for treating and/or limiting development of diabetes
US9125255B2 (en) 2012-05-03 2015-09-01 Abl Ip Holding Llc Networked architecture for system of lighting devices having sensors, for intelligent applications
US9901562B2 (en) 2013-04-04 2018-02-27 Lycored Ltd. Anti-inflammatory omega-3 synergistic combinations
BR112020008514A2 (pt) * 2017-10-31 2020-10-20 Staten Biotechnology B.V. anticorpos anti-apoc3 e métodos de uso dos mesmos
CN114354827A (zh) * 2022-03-21 2022-04-15 天津云检医疗器械有限公司 代谢标志物及其在制备2型糖尿病的风险预测试剂盒中的应用和试剂盒

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164818A1 (en) * 1995-05-23 2002-11-07 Gruber Karl F. Mass spectrometric immunoassay analysis of specific proteins and variants present in various biological fluids
JP2005503537A (ja) * 2001-01-17 2005-02-03 エー. タブス,ケモンズ 生体分子分析用ハイ・スループット統合システム
CA2434699A1 (en) * 2001-01-17 2002-10-17 Randall W. Nelson An integrated high throughput system for the analysis of biomolecules
US6677303B2 (en) * 2001-04-30 2004-01-13 Syn X Pharma Biopolymer marker indicative of disease state having a molecular weight of 1097 daltons
US9062306B2 (en) * 2003-04-29 2015-06-23 Biocrine Ab Methods for identifying compounds for treating type 1 diabetes
US20070087448A1 (en) * 2004-02-16 2007-04-19 Nelsestuen Gary L Biological profiles and methods of use
US8343534B2 (en) * 2004-04-23 2013-01-01 The Procter & Gamble Company Tissue including a volatile rhinological composition
US20060110082A1 (en) * 2004-11-24 2006-05-25 Sauer-Danfoss Inc. Compact unitized cradle swashplate bearing
JPWO2006073195A1 (ja) * 2005-01-07 2008-06-12 敏一 吉川 糖尿病の予知・診断方法および糖尿病予知・診断用キット
CN101166981A (zh) * 2005-04-11 2008-04-23 阿斯利康(瑞典)有限公司 一种用于诊断 2型糖尿病、代谢综合征、亚临床动脉粥样硬化、心肌梗死、中风或糖尿病的临床表现的方法和试剂盒
US20070055341A1 (en) * 2005-08-26 2007-03-08 Vascular And Endovascular Surgical Technologies, Inc. Endograft
US20070112055A1 (en) * 2005-09-30 2007-05-17 Glenmark Pharmaceuticals Limited Crystalline forms of almotriptan and processes for their preparation
JP5688829B2 (ja) * 2005-11-11 2015-03-25 敏一 吉川 示差的な糖尿病の予知・診断方法および糖尿病予知・診断用キット
EP2005172A4 (en) * 2006-03-23 2009-05-06 Emelita De Guzman Breyer APOLIPOPROTEIN-FINGERPRINT PROCESS
JP2009537812A (ja) * 2006-05-15 2009-10-29 デジラブ インコーポレーテッド 2型糖尿病プリフォームのバイオマーカー、及び2型糖尿病プリフォームの存在又は不在を検出する方法
US20080300170A1 (en) * 2006-09-01 2008-12-04 Cohava Gelber Compositions and methods for diagnosis and treatment for type 2 diabetes

Similar Documents

Publication Publication Date Title
Viswanath et al. Recent trends in the development of diagnostic tools for diabetes mellitus using patient saliva
Postuma et al. Clinical prediction of Parkinson's disease: planning for the age of neuroprotection
Choudhary et al. Frequency of biochemical hypoglycaemia in adults with type 1 diabetes with and without impaired awareness of hypoglycaemia: no identifiable differences using continuous glucose monitoring
Mayega et al. Comparison of fasting plasma glucose and haemoglobin A1c point-of-care tests in screening for diabetes and abnormal glucose regulation in a rural low income setting
Sung et al. Progressive axonal dysfunction precedes development of neuropathy in type 2 diabetes
WO2010053587A3 (en) Methods of monitoring conditions by sequence analysis
Lin et al. Investigation on cardiovascular risk prediction using physiological parameters
JP2012533066A5 (enExample)
WO2014110492A3 (en) Saliva glucose monitoring system
EP2369346A3 (en) Means and method for diagnosing diabetes
JP2011516046A5 (enExample)
WO2009036429A3 (en) Improved quality assurance system and method for point-of-care testing
JP2012068263A5 (enExample)
JP2020512550A5 (enExample)
JP2020517919A5 (enExample)
WO2011088128A3 (en) Methods for biomolecule and biomolecule complex (bmc) detection and analysis and the use of such for research and medical diagnosis
Bresciani et al. Accuracy of capillary blood 3-β-hydroxybutyrate determination for the detection and treatment of canine diabetic ketoacidosis
Sharma et al. Predictors of minimal hepatic encephalopathy in patients with cirrhosis
ATE537454T1 (de) Verfahren zum beurteilen von herzinsuffizienz bei patienten mit vorhofflimmern mittels gdf-15
KR20170002318A (ko) 대사체 분석을 이용한 당뇨병 조기 진단용 조성물
Zhang et al. A strategy for the development of biomarker tests for PTSD
FI13179Y1 (fi) Laite aivovamman havaitsemiseksi kohteessa
Ma et al. Evaluation of sweat-based biomarkers using wearable biosensors for monitoring stress and fatigue: a systematic review
WO2009133197A3 (en) Levels of april in serum and use in diagnostic methods
JP2012533065A5 (enExample)